Company / SG&A Expense
Insight Molecular Diagnostics Inc. SG&A Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$10.2M
FY2025
5-year range
$10.2M / $22.3M
FY2021-FY2025
Trend
-8.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has declined for 3 consecutive years, from $22M in FY2022 to $10M in FY2025.
Based on SEC 10-K filings.
$10M in FY2025 with a 5-year CAGR of -5.1%.
Improved from $22M to $10M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -22.9%
- 5-Year CAGR
- -5.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- Insight Molecular Diagnostics Inc.'s sg&a expense has declined for 3 consecutive years.
- 5-year CAGR of -5.1%, indicating a declining trend.
- In FY2025, sg&a expense decreased 8.7% year-over-year.
- Peak sg&a expense was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -7.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.2M | -8.7% |
| FY2024 | $11.2M | -48.9% |
| FY2023 | $21.9M | -1.8% |
| FY2022 | $22.3M | +32.8% |
| FY2021 | $16.8M | +26.4% |
| FY2020 | $13.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026